Clearmind Medicine Reports Continued Progress In Third Cohort Of Phase I/IIa Trial Evaluating CMND-100 For Alcohol Use Disorder

Clearmind Medicine, a clinical-stage biotechnology company developing novel, non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for major under-treated health conditions, announced the successful continuation of treatment for participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100. The investigational oral therapy is based on the company’s proprietary non-hallucinogenic MEAI compound and is being studied for its potential to treat Alcohol Use Disorder (AUD).

The update follows Clearmind’s announcement on March 11, 2026, confirming advancement of participant enrollment for the third cohort at three sites: Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. Patients at the U.S. sites—Yale University and Johns Hopkins University—are continuing treatment as planned, with ongoing assessments indicating steady progress, favorable tolerability, and no serious adverse events reported to date.

The Phase I/IIa study is a multinational, multicenter clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in individuals with moderate to severe AUD. The continued successful treatment of participants at major U.S. medical institutions underscores growing momentum around the program and supports the potential of CMND-100 as a novel therapeutic option for Alcohol Use Disorder, a condition with limited effective treatments.

Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, said the latest milestone builds on positive topline data from earlier cohorts. She noted that the ongoing progress at U.S. clinical sites reflects the company’s confidence in CMND-100 and reinforces the importance of developing innovative, non-hallucinogenic neuroplasticity-enhancing treatments for AUD.